University of California, San Francisco
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of California, San Francisco sits in the top decile of US sponsors by registered trial count (#10 of 15,742 sponsors by registered trial count).
University of California, San Francisco: 1,713 sponsored US clinical trials, 272 recruiting.
University of California, San Francisco sponsors 1,713 registered US clinical trials on ClinicalTrials.gov, 272 of them currently recruiting, and 1,130 completed. 196 of these trials are in Phase 3-4 (later-stage) and 359 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 18 trials.
Top-decile sponsor footprint
University of California, San Francisco ranks in the top decile of sponsors by registered trial count (#10 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,130 of 1,305 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,713 total, page 14 of 35
Impact of Phone Call About Financial Reimbursement Program on Access to Cancer Clinical Trials
NCT03943082
Inflammation and Threat Sensitivity in PTSD
NCT03048929
Continuous Versus Cyclical OCP Use in PCOS
NCT03819140
Short-Term Cardiovascular Effects of E-Cigarettes: Influence of Device Power
NCT03839745
Vaping THC From Electronic Cigarettes
NCT02955329
Individualized Studies of Triggers of Paroxysmal Atrial Fibrillation
NCT03323099
Rapid Detection of Airway Pathogens for Lung Transplantation
NCT03933878
Reducing Breast Cancer Risk in Korean American Women
NCT04079556
De-escalating Vital Sign Checks
NCT04046458
A Group-Based Therapeutic Yoga Intervention for Urinary Incontinence in Ambulatory Older Women
NCT03672461
Lung Cancer Screening: A Multilevel Intervention
NCT03862001
The Effect of NAC on Lung Function and CT Mucus Score
NCT03822637
The Impact of 8 Weeks of Digital Meditation Application and Healthy Eating Program on Work Stress and Health Outcomes
NCT03945214
Tech and Telephone Smoking Cessation Treatment for Young Veterans With PTSD
NCT03552978
Livionex on Reducing Plaque Accumulation and Improving Oral Health in Children
NCT04368533
The Share Health Study: Teen Social Connections and Health (Phase 2)
NCT03842540
Virtual Reality- Working Memory Retraining
NCT03786276
Sphenopalatine Ganglion Blocks RCT
NCT03666663
Pilot Human Laboratory Study of Alcohol Approach Bias Modification (AABM) for Alcohol Use Disorder (AUD)
NCT03898323
The Effect of SLC19A3 Inhibition on the Pharmacokinetics of Thiamine
NCT03746106
Pragmatic Research of Acupuncture and Counseling eXtended to Inpatient Services
NCT03905720
Improving Access to Care: Testing an Integrated Care Mobile Health Intervention
NCT03780088
Spironolactone Therapy In Young Women With NASH
NCT03576755
Connection to Health for Smokers
NCT03680599
Ultrasound First Clinical Decision Support for Suspected Nephrolithiasis
NCT03461536
Comparison Of Rocuronium Reversal By Sugammadex To Succinylcholine For Electroconvulsive Therapy (ECT)
NCT03532178
Minimally Invasive Thoracic Surgery Intercostal Nerve Block Trial
NCT03508830
Ancillary Study of the Lessening Incontinence With Low-impact Activity Study
NCT04776720
Evaluating the Role of Inflammation in Neonatal Epileptogenesis
NCT04259125
Patient Portal and Navigation Program in Providing Information for Asian American Cancer Patients
NCT03867916
(R33 Phase) DELISH Study: Diabetes Education to Lower Insulin, Sugars, and Hunger
NCT03837405
Technology and Telephone-Based Smoking Cessation
NCT03492645
Efficacy of Bromocriptine For Fever Reduction in Acute Neurologic Injury
NCT03496545
Impact of a Lower Extremity Amputation Pathway Protocol in Dysvascular Patients
NCT03592316
Study to Understand Gaining Access to Blood Glucose Records
NCT02956642
The Impact of Dupilumab on Quality of Life in Moderate to Severe Atopic Dermatitis Patients
NCT03667014
Improving the HIV PrEP Cascade Using an Intervention for Healthcare Providers
NCT03532191
Tissue-specific Insulin Resistance in Obstructive Sleep Apnea: Role of Hypoxia
NCT03695315
Acute Pain Management in Patients on Opioid Replacement Therapy
NCT03933865
An Extended Facebook Intervention for Young Sexual and Gender Minority Smokers
NCT03553992
Effect of Changing Physiological Conditions on Myogenic Oscillations: Pilot Study
NCT03719001
Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis
NCT03293030
Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib
NCT03094052
Home Outpatient Monitoring and Engagement to Predict HF Exacerbation
NCT03479424
High School Start Time and Teen Migraine Frequency
NCT03766412
TSA Exercise Prehabilitation in Older Adults
NCT03212300
Using the Electronic Health Record to Guide Management of Newborn Weight Loss
NCT03655314
Post-Injury Platelet Biology: Mechanisms and Outcomes
NCT03682757
Self Sampling for Rapid Turnaround Testing in the Emergency Department
NCT03676816
Pilot Human Lab Study of Lacosamide in Alcohol Use Disorder (AUD)
NCT03897348
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 193 |
| Phase 2 | 166 |
| Phase 3 | 44 |
| Phase 4 | 152 |
Therapeutic Areas
What is open in the University of California, San Francisco pipeline
272 recruiting of 1,713 indexed (16% open); 1,130 completed (66%).
Phase mix: 196 late (III/IV) vs 359 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (18 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of California, San Francisco: open-pipeline peers nationwide
Peers matched on 1,713 registered trials and 16% open enrollment, not the therapeutic-area sidebar.
University of California, San Francisco sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,713 trials (± recruiting share)
- Duke University · 1,725 trials · 11% recruiting
- Stanford University · 1,744 trials · 15% recruiting
- VA Office of Research and Development · 1,668 trials · 17% recruiting
- Pfizer · 1,845 trials · 6% recruiting
Sponsors near 16% open enrollment (± trial volume)
- University of Oregon · 16% recruiting · 63 trials
- Fox Chase Cancer Center · 16% recruiting · 183 trials
- Youngstown State University · 16% recruiting · 19 trials
- ECOG-ACRIN Cancer Research Group · 16% recruiting · 75 trials
Related
What to do with this University of California, San Francisco page
1,713 registered trials is a research-attention snapshot, not an endorsement of University of California, San Francisco or any single study.
- 272 of University of California, San Francisco's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition University of California, San Francisco studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of California, San Francisco pipeline card: 1,713 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.